Literature DB >> 7673336

Regulation of mesenchymal extracellular matrix protein synthesis by transforming growth factor-beta and glucocorticoids in tumor stroma.

J F Talts1, A Weller, R Timpl, M Ekblom, P Ekblom.   

Abstract

We have here studied the composition and regulation of stromal extracellular matrix components in an experimental tumor model. Nude mice were inoculated with WCCS-1 cells, a human Wilms' tumor cell line. In the formed tumors the stroma was found to contain mesenchymal extracellular matrix proteins such as tenascin-C, fibulins-1 and 2 and fibronectin, but no nidogen. Nidogen was confined to basement membranes of tumor blood vessels. Since glucocorticoids have been shown to downregulate tenascin-C expression in vitro, we tested whether dexamethasone can influence biosynthesis of extracellular matrix components during tumor formation in vivo. A downregulation of tenascin-C mRNA and an upregulation of fibronectin mRNA expression by dexamethasone was noted. Transforming growth factor-beta 1 mRNA levels were unaffected by the dexamethasone treatment. Glucocorticoids can thus downregulate tenascin-C synthesis although local stimulatory growth factors are present. The competition between a negative and a positive extrinsic factor on synthesis of stromal extracellular matrix components was studied in a fibroblast/preadipocyte cell line. Transforming growth factor-beta 1 stimulated tenascin-C synthesis but did not affect fibronectin or fibulin-2 synthesis. Dexamethasone at high concentrations could completely suppress the effect of transforming growth factor-beta 1 on tenascin-C mRNA expression. Transforming growth factor-beta 1 could in turn overcome the downregulation of tenascin-C mRNA expression caused by a lower concentration of dexamethasone. We therefore suggest that the limited expression of tenascin-C in part is due to a continuous suppression by physiological levels of glucocorticoids, which can be overcome by local stimulatory growth factors when present in sufficient amounts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673336     DOI: 10.1242/jcs.108.6.2153

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  7 in total

Review 1.  Fibulins: physiological and disease perspectives.

Authors:  W Scott Argraves; Lisa M Greene; Marion A Cooley; William M Gallagher
Journal:  EMBO Rep       Date:  2003-12       Impact factor: 8.807

2.  Characterization of mouse fibronectin alternative mRNAs reveals an unusual isoform present transiently during liver development.

Authors:  G K Górski; M C Aros; P A Norton
Journal:  Gene Expr       Date:  1996

3.  miR-29c induction contributes to downregulation of vascular extracellular matrix proteins by glucocorticoids.

Authors:  Tsai-Der Chuang; William J Pearce; Omid Khorram
Journal:  Am J Physiol Cell Physiol       Date:  2015-05-27       Impact factor: 4.249

4.  Augmented expression of urokinase plasminogen activator and extracellular matrix proteins associates with multiple myeloma progression.

Authors:  Rehan Khan; Nidhi Gupta; Raman Kumar; Manoj Sharma; Lalit Kumar; Alpana Sharma
Journal:  Clin Exp Metastasis       Date:  2014-05-08       Impact factor: 5.150

5.  Fibroblast growth factor signaling and basement membrane assembly are connected during epithelial morphogenesis of the embryoid body.

Authors:  X Li; Y Chen; S Schéele; E Arman; R Haffner-Krausz; P Ekblom; P Lonai
Journal:  J Cell Biol       Date:  2001-05-14       Impact factor: 10.539

6.  Transcriptional regulation of tenascin-W by TGF-beta signaling in the bone metastatic niche of breast cancer cells.

Authors:  Francesca Chiovaro; Enrico Martina; Alessia Bottos; Arnaud Scherberich; Nancy E Hynes; Ruth Chiquet-Ehrismann
Journal:  Int J Cancer       Date:  2015-04-29       Impact factor: 7.396

Review 7.  Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments.

Authors:  Wentao Tian; Yi Liu; Chenghui Cao; Yue Zeng; Yue Pan; Xiaohan Liu; Yurong Peng; Fang Wu
Journal:  Front Cell Dev Biol       Date:  2021-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.